Amino Acid, Peptide, or Protein – Page 6

Eli Lilly Withdraws $1.9B Phase 2b Obesity Trial Before Launching Enrollment

1 month ago talkbio0Tagged bimagrumab, Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Eli, Eli Lilly, Obesity, regulatory strategy, tirzepatide, Trial Termination, Zepbound

Eli Lilly; obesity drug; tirzepatide; bimagrumab; trial termination; phase 2b; Zepbound; type 2 diabetes; clinical trial; regulatory strategy

Pfizer’s $4.9B Metsera Deal Signals More Pharma M&A in Booming Obesity Drug Market

1 month ago talkbio0Tagged biotech acquisition, Glucagon-Like Peptide 1, late-stage clinical development, M&A, Metsera, Obesity, Pfizer, Pharma, pharmaceutical market, Weight Loss

Pfizer; Metsera; obesity drugs; weight loss; pharma M&A; GLP-1; biotech acquisition; pharmaceutical market; late-stage clinical development

Eli Lilly Invests $6.5 Billion in Texas Facility to Manufacture Obesity Pill

1 month ago talkbio0Tagged alpha 1-antitrypsin, Artificial Intelligence, Automation, Contraceptives, Oral, eli lilly, Obesity, orforglipron, pharmaceutical manufacturing, Supply Chain Resilience, Surgical construction, Texas Facility

Eli Lilly; Texas facility; obesity pill; orforglipron; pharmaceutical manufacturing; API; AI automation; supply chain resilience; job creation

Acadia Pulls Plug on Prader-Willi Drug After Phase 3 Trial Failure

1 month ago talkbio0Tagged Acadia, ACP-101, carbetocin, Clinical trial failure, Hyperphagia, Prader-Willi Syndrome, Soleno, Vykat XR

Acadia Pharmaceuticals; Prader-Willi syndrome; carbetocin; ACP-101; phase 3 trial; hyperphagia; clinical trial failure; Soleno Therapeutics; Vykat XR

Acadia Halts Development of Nasal Prader-Willi Drug After Phase 3 Failure

1 month ago talkbio0Tagged Acadia, carbetocin, Clinical trial failure, Compass, Hyperphagia, Nasal Spray, Prader-Willi Syndrome

Acadia Pharmaceuticals; carbetocin; Prader-Willi syndrome; Phase 3 trial; COMPASS PWS study; clinical trial failure; nasal spray; hyperphagia

Eli Lilly Picks Houston for $6.5 Billion API Manufacturing Facility

1 month ago talkbio0Tagged alpha 1-antitrypsin, cardiometabolic, Eli, Eli Lilly, Generation Park, Houston, Immunology, Investments, Manufacturing, Neoplasms, Neuroscience discipline, pharmaceutical manufacturing, small molecule medicines

Eli Lilly; Houston; API manufacturing; $6.5 billion investment; Generation Park; small molecule medicines; pharmaceutical manufacturing; cardiometabolic; oncology; immunology; neuroscience

FDA Rejects Scholar Rock’s SMA Drug Due to Catalent Indiana Manufacturing Issues

1 month ago talkbio0Tagged apitegromab, Catalent Indiana, Complete, Drug Approval, manufacturing issues, Response Letter, Scholar Rock, SMA, Spinal Muscular Atrophy, United States Food and Drug Administration

FDA; Scholar Rock; Apitegromab; SMA; Spinal Muscular Atrophy; Catalent Indiana; Complete Response Letter; Manufacturing issues; Drug approval

Fierce Biotech Fundraising Tracker ’25: Avenzo adds $60M Series B; Ollin debuts with $100M

1 month ago talkbio0Tagged Antibodies, Bispecific, Avenzo, Clinical Trials, Neoplasms, Ollin Biosciences, Ophthalmology specialty, pipeline development, Series B financing, venture capital

Avenzo Therapeutics; Series B financing; Ollin Biosciences; biotech fundraising; oncology; ophthalmology; venture capital; pipeline development; bispecific antibody; clinical trials